Modern Management of Pregnancy in Systemic Lupus Erythematosus: From Prenatal Counseling to Postpartum Support
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnancy in SLE patients poses unique challenges due to the potential impact on maternal and fetal outcomes. We provide an overview of the management of SLE during pregnancy, including preconception risk stratification and counseling, treatment, and disease activity monitoring. These assessments are critical to minimize maternal and fetal adverse events in pregnant patients with SLE. Disease flares, preeclampsia, antiphospholipid syndrome complications, and maternal mortality are the major risks for a woman with SLE during gestation. Timely treatment of SLE relapse, differentiation of preeclampsia from lupus nephritis, and tailored management for antiphospholipid syndrome are essential for a successful pregnancy. Fetal outcomes include neonatal lupus (NL), preterm birth, cesarean delivery, fetal growth restriction (FGR), and small-for-gestational-age (SGA) infants. We focused on NL, linked to maternal anti-Ro/SS-A and anti-La/SS-B antibodies, which can lead to various manifestations, particularly cardiac abnormalities, in newborns. While there is a common consensus regarding the preventive effect of hydroxychloroquine, the role of echocardiographic monitoring and fluorinated steroid treatment is still debated. Finally, close postpartum monitoring and counseling for subsequent pregnancies are crucial aspects of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pregnant patients with autoimmune conditions are at greater risk for developing adverse pregnancy outcomes.133,134”
From Guidelines for antenatal and preoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 1)—2025 update (2026) · cites this paper as [134]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318 · cited 1×
“According to the 2019 EULAR recommendations [59], pregnant patients with SLE and a high-risk aPL profile, without previous thrombotic or pregnancy episodes, should be treated with LDA (75–100 mg/day) during pregnancy.”
MethodCombined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Perinatal mental illness: Definition, description and aetiology
O'Hara, M. W., & Wisner, K. L. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.09.002 · Cited by 986 · cited 1×
“Additionally, it is important to remember that the prevalence of postpartum depression in Europe is estimated to be around 10% [91].”
BackgroundAndreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Fischer-Betz, R., Forger, F., Moraes-Fontes, M. F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209770 · Cited by 945 · cited 8×
“Indeed, it can contribute in maintaining disease control, and its discontinuation has been linked to an increased risk of flares during pregnancy [7].”
BackgroundMethodResultInfluentialSelf-citationPre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis
Ananth, C. V., Keyes, K. M., & Wapner, R. J. (2013) · BMJ · doi:10.1136/bmj.f6564 · Cited by 940 · cited 1×
“Between 20% and 30% of SLE pregnancies are at risk of developing PE [38,44,45].”
BackgroundSammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41191 · Cited by 790 · cited 4×
“Several studies [2] showed that the number of pregnancies in patients with systemic lupus erythematosus (SLE) is lower than in the general population.”
BackgroundInfluentialRoberge, S., Nicolaides, K., Demers, S., Hyett, J., Chaillet, N., & Bujold, E. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.09.076 · Cited by 679 · cited 1×
“A meta-analysis involving over 20,000 pregnant women revealed that when LDA was given before 16 weeks, there were significant dose-dependent reductions in the rates of FGR [90].”
MethodSmyth, A., Oliveira, G. H. M., Lahr, B. D., Bailey, K. R., Norby, S. M., & Garovic, V. D. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240110 · Cited by 660 · cited 2×
“The risk increased in cases of active disease or renal flares [40,88,89].”
BackgroundA national study of the complications of lupus in pregnancy
Clowse, M. E. B., Jamison, M., Myers, E., & James, A. H. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.03.012 · Cited by 609 · cited 1×
“In a US national study of 13,555 SLE pregnancies from 2000 to 2003, Clowse et al. [60] found that the risk of maternal death (325/100,000 live births) was more than 20-fold higher than in the non-SLE population.”
BackgroundPredictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study
Buyon, J. P., Kim, M. Y., Guerra, M. M., Laskin, C. A., Petri, M., Lockshin, M. D., Sammaritano, L., Branch, D. W., Porter, T. F., Sawitzke, A., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2235 · Cited by 567 · cited 2×
“Notably, most disease flares during pregnancy affect the same organs involved before pregnancy [11,12].”
BackgroundHydroxychloroquine in lupus pregnancy
Clowse, M. E. B., Magder, L., Witter, F., & Petri, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22159 · Cited by 529
2023 ACR/EULAR antiphospholipid syndrome classification criteria
Barbhaiya, M., Zuily, S., Naden, R., Hendry, A., Manneville, F., Amigo, M.-C., Amoura, Z., Andrade, D., Andreoli, L., Artim-Esen, B., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224609 · Cited by 493 · cited 1×
“In 2023, ACR/EULAR [58] criteria for APS were established.”
BackgroundIzmirly, P. M., Costedoat-Chalumeau, N., Pisoni, C. N., Khamashta, M. A., Kim, M. Y., Saxena, A., Friedman, D., Llanos, C., Piette, J.-C., & Buyon, J. P. (2012) · Circulation · doi:10.1161/circulationaha.111.089268 · Cited by 456
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Levy, R. A., Vilela, V. S., Cataldo, M. J., Ramos, R. C., Duarte, J. L., Tura, B. R., Albuquerque, E. M., & Jesús, N. R. (2001) · Lupus · doi:10.1191/096120301678646137 · Cited by 398
A Trial of Contraceptive Methods in Women with Systemic Lupus Erythematosus
Sánchez-Guerrero, J., Uribe, A. G., Jiménez-Santana, L., Mestanza-Peralta, M., Lara-Reyes, P., Seuc, A. H., & Cravioto, M.-D.-C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050817 · Cited by 352 · cited 1×
“However, several studies [5–7] have shown the safety profile of contraception with E-P pills and copper intrauterine devices (IUDs) in patients with inactive diseases, while the use of medicated IUDs should only be considered in specific cases where the benefits outweigh the thrombotic risk [8].”
ResultBullo, M., Tschumi, S., Bucher, B. S., Bianchetti, M. G., & Simonetti, G. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.196352 · Cited by 334 · cited 1×
“ACE inhibitors/angiotensin receptor blockers (ARBs), prescribed for lupus nephritis as antihypertensive and antiproteinuric agents, should be discontinued due to the associated risk of fetal complications, including IUGR, cardiac and renal abnormalities, limb malformations, and oligohydramnios [26].”
BackgroundThe clinical spectrum of autoimmune congenital heart block
Brito-Zerón, P., Izmirly, P. M., Ramos-Casals, M., Buyon, J. P., & Khamashta, M. A. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.29 · Cited by 305 · cited 1×
“However, when both anti-Ro/SS-A and anti-La/SS-B antibodies are present, the likelihood of NL increases [63].”
BackgroundChakravarty, E. F., Colón, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.02.063 · Cited by 280 · cited 1×
“Between 20% and 30% of SLE pregnancies are at risk of developing PE [38,44,45].”
BackgroundJaeggi, E., Laskin, C., Hamilton, R., Kingdom, J., & Silverman, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.042 · Cited by 273 · cited 1×
“Buyon J. in 1993 [64] and Jaeggi E. in 2010 [65] showed that the lower the antibody titer, the lower the risk of newborn lupus.”
BackgroundRussell, M. D., Dey, M., Flint, J., Davie, P., Allen, A., Crossley, A., Frishman, M., Gayed, M., Hodson, K., Khamashta, M., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/keac551 · Cited by 236 · cited 4×
“Notably, most disease flares during pregnancy affect the same organs involved before pregnancy [11,12].”
BackgroundInfluentialIzmirly, P., Kim, M., Friedman, D. M., Costedoat-Chalumeau, N., Clancy, R., Copel, J. A., Phoon, C. K. L., Cuneo, B. F., Cohen, R. E., Robins, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.045 · Cited by 226 · cited 1×
“In contrast, several studies [79–81] have demonstrated that the use of HCQ from the early GWs reduces the risk of NL, even in cases of NL in previous pregnancies.”
ResultKwok, L.-W., Tam, L.-S., Zhu, T., Leung, Y.-Y., & Li, E. (2011) · Lupus · doi:10.1177/0961203310397967 · Cited by 215 · cited 1×
“Additionally, factors applicable to the general population should be taken into consideration, including a woman’s age, diabetes mellitus, arterial hypertension, obesity, thyroid disorders, smoking/alcohol habits, and vaccination status [10].”
BackgroundBuyon, J. P., Winchester, R. J., Slade, S. G., Arnett, F., Copel, J., Friedman, D., & Lockshin, M. D. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360911 · Cited by 204 · cited 1×
“Buyon J. in 1993 [64] and Jaeggi E. in 2010 [65] showed that the lower the antibody titer, the lower the risk of newborn lupus.”
BackgroundKidney biopsy in pregnancy: evidence for counselling? A systematic narrative review
Piccoli, G., Daidola, G., Attini, R., Parisi, S., Fassio, F., Naretto, C., Deagostini, M., Castelluccia, N., Ferraresi, M., Roccatello, D., et al. (2013) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12111 · Cited by 200 · cited 1×
“They reference two studies, one from 2013 involving 197 pregnancy-related biopsies [47] and another from 2015 covering 11 pregnancies [48].”
BackgroundPoon, L. C., Wright, D., Rolnik, D. L., Syngelaki, A., Delgado, J. L., Tsokaki, T., Leipold, G., Akolekar, R., Shearing, S., De Stefani, L., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.07.038 · Cited by 198 · cited 1×
“As demonstrated in the ASPRE (Aspirin for Evidence-Based Preeclampsia Prevention) trial [50], initiating 150mg/day of LDA before the 16th GW reduces the risk of PE in high-risk women.”
MethodAssessing disease activity in SLE patients during pregnancy
Buyon, J. P., Kalunian, K. C., Ramsey-Goldman, R., Petri, M. A., Lockshin, M. D., Ruiz-Irastorza, G., & Khamashta, M. (1999) · Lupus · doi:10.1191/096120399680411272 · Cited by 191 · cited 1×
“…pregnancy such as the SLE-Pregnancy Disease Activity Index (SLEPDAI), the Lupus Activity Index (LAI) in Pregnancy (LAI-P), modified SLAM (m-SLAM) [33], modified-European consensus lupus activity measurement (m-ECLAM) [34,35], and the British Isles Lupus Assessment Group-2004 for pregnancy…”
The geoepidemiology of the antiphospholipid antibody syndrome
Biggioggero, M., & Meroni, P. L. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.11.013 · Cited by 187 · cited 1×
“The prevalence of aPLs in patients with SLE is 12–44% for anticardiolipin antibodies (aCL), 15–34% for lupus anticoagulant (LAC), and 10–19% for anti - β 2GPI [55].”
BackgroundEffects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes
Namazy, J. A., Murphy, V. E., Powell, H., Gibson, P. G., Chambers, C., & Schatz, M. (2013) · European Respiratory Journal · doi:10.1183/09031936.00195111 · Cited by 178 · cited 1×
“Risk is also related to the administration of oral PDN [84,85] and dysfunctions in the maternal or fetal hypothalamic–pituitary axis, which result in elevated placental corticotropin-releasing hormone levels, leading to increased synthesis of cortisol and prostaglandins [86].”
BackgroundPreterm deliveries in women with systemic lupus erythematosus.
Clark, C. A., Spitzer, K. A., Nadler, J. N., & Laskin, C. A. (2003) · PubMed · Cited by 176
Maternal and foetal outcomes in pregnant patients with active lupus nephritis
Wagner, S., Craici, I., Reed, D., Norby, S., Bailey, K., Wiste, H., Wood, C., Moder, K., Liang, K., Liang, K., et al. (2009) · Lupus · doi:10.1177/0961203308097575 · Cited by 163 · cited 1×
“[41,42].”
Neonatal lupus: Follow-up in infants with anti -SSA/Ro antibodies and review of the literature
Zuppa, A. A., Riccardi, R., Frezza, S., Gallini, F., Luciano, R., Alighieri, G., Romagnoli, C., & Carolis, S. D. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.02.010 · Cited by 153 · cited 1×
“Only LAI-P has been validated [37].”
Agmon‐Levin, N., Blank, M., Zandman‐Goddard, G., Orbach, H., Meroni, P. L., Tincani, A., Doria, A., Cervera, R., Miesbach, W., Stojanovich, L., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134817 · Cited by 152
Self-citationLévesque, K., Morel, N., Maltret, A., Baron, G., MASSEAU, A., ORQUEVAUX, P., Pietté, J. C., Barrière, F., Bidois, J. L., Fermont, L., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.08.005 · Cited by 150 · cited 1×
“However, multiple studies [75,76] show that first-degree block does not worsen in fetuses with untreated mothers.”
BackgroundGómez‐Guzmán, M., Jiménez, R., Romero, M., Sánchez, M., Zarzuelo-Romero, M. J., Gómez‐Morales, M., O’Valle, F., López-Farré, A. J., Algieri, F., Gálvez, J., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03587 · Cited by 146 · cited 1×
“Multiple studies [52–54] have indicated that HCQ reduces the synthesis of reactive oxygen species (ROS) and, consequently, their associated damage.”
BackgroundThe Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal Complications
Gladman, D. D., Tandon, A., Ibañez, D., & Urowitz, M. B. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090872 · Cited by 135 · cited 1×
“The risk increased in cases of active disease or renal flares [40,88,89].”
BackgroundHydroxychloroquine early in pregnancy and risk of birth defects
Huybrechts, K. F., Bateman, B. T., Zhu, Y., Straub, L., Mogun, H., Kim, S. C., Desai, R. J., & Hernández–Díaz, S. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.09.007 · Cited by 134
Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus
Doria, A., Cutolo, M., Ghirardello, A., Zampieri, S., Vescovi, F., Sulli, A., Giusti, M., Piccoli, A., Grella, P., & Gambari, P. F. (2002) · Arthritis Care & Research · doi:10.1002/art.10248 · Cited by 130 · cited 2×
“Indeed, SLE patients often exhibit reduced levels of estradiol, which are directly proportional to placental health [34].”
BackgroundSelf-citationSystemic Lupus Erythematosus Management in Pregnancy
Dao, K. H., & Bermas, B. L. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s282604 · Cited by 129 · cited 1×
“This drug is particularly recommended for patients with PE risk factors, including extreme age, primigravida status, arterial hypertension, pre-existing renal conditions, and aPLs [49].”
BackgroundMoroni, G. L., Doria, A., Giglio, E., Tani, C., Zen, M., Strigini, F. A. L., Zàina, B., Tincani, A., de Liso, F., Matinato, C., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.010 · Cited by 128 · cited 2×
“Moroni et al. [87] identified risk predictors for preterm delivery which include SLEDAI, active nephritis, proteinuria (g/day), arterial hypertension, previous renal flares, quarterly change in a single unit in SLEDAI, and quarterly increase in daily proteinuria >1 g during pregnancy.”
BackgroundSelf-citationDisease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus
Rivera, T. L., Izmirly, P., Birnbaum, B. K., Byrne, P., Brauth, J. B., Katholi, M., Kim, M. Y., Fischer, J., Clancy, R. M., & Buyon, J. P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088054 · Cited by 119 · cited 1×
“Notably, 50% of mothers of infants born with NL will develop the autoimmune disease after pregnancy [68].”
BackgroundMehta, B. Y., Luo, Y., Xu, J. C., Sammaritano, L. R., Salmon, J. E., Lockshin, M. D., Goodman, S. M., & Ibrahim, S. A. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0120 · Cited by 117 · cited 2×
“Between 20% and 30% of SLE pregnancies are at risk of developing PE [38,44,45].”
BackgroundEnvironment and systemic lupus erythematosus: An overview
Sarzi‐Puttini, P., Atzeni, F., Iaccarino, L., & Doria, A. (2005) · Autoimmunity · doi:10.1080/08916930500285394 · Cited by 115 · cited 1×
“The cause is unknown; however, a number of genetic and environmental factors have been identified [1].”
BackgroundSelf-citationAutoantibodies and Prediction of Reproductive Failure
Shoenfeld, Y., Carp, H. J. A., Molina, V., Blank, M., Cervera, R., Balasch, J., Tincani, A., Faden, D., Lojacono, A., Doria, A., et al. (2006) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2006.00434.x · Cited by 110 · cited 1×
“Antiphospholipid and anti-prothrombin antibodies were reported at higher levels in patients with infertility compared to controls [4].”
BackgroundSelf-citationPregnancy, cytokines, and disease activity in systemic lupus erythematosus
Doria, A., Ghirardello, A., Iaccarino, L., Zampieri, S., Punzi, L., Tarricone, E., Ruffatti, A., Sulli, A., Sarzi‐Puttini, P. C., Gambari, P. F., et al. (2004) · Arthritis Care & Research · doi:10.1002/art.20837 · Cited by 109 · cited 1×
“…such as the SLE-Pregnancy Disease Activity Index (SLEPDAI), the Lupus Activity Index (LAI) in Pregnancy (LAI-P), modified SLAM (m-SLAM) [33], modified-European consensus lupus activity measurement (m-ECLAM) [34,35], and the British Isles Lupus Assessment Group-2004 for pregnancy (BILAG2004-P) [36].”
BackgroundSelf-citationPregnancy in systemic lupus erythematosus and antiphospholipid syndrome
Fischer‐Betz, R., & Specker, C. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.09.011 · Cited by 109 · cited 2×
“There have been no controlled studies assessing the effectiveness of plasmapheresis in cardiac NL. IVIGs were not demonstrated to prevent cardiac NL at a dose of 400 mg/kg [78].”
BackgroundHome Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies
Cuneo, B. F., Sonesson, S., Levasseur, S. M., Moon‐Grady, A. J., Krishnan, A. N., Donofrio, M. T., Raboisson, M., Hornberger, L. K., Eerden, P. V., Sinkovskaya, E. S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.076 · Cited by 109 · cited 2×
“However, some studies [73] are questioning the usefulness of this approach, since only rarely has standard fetal heart rate surveillance detected CHB in time for effective treatment.”
BackgroundMaternal outcome in pregnant women with lupus nephritis. A prospective multicenter study
Moroni, G. L., Doria, A., Giglio, E., Imbasciati, E., Tani, C., Zen, M., Strigini, F. A. L., Zàina, B., Tincani, A., Gatto, M., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.012 · Cited by 107 · cited 1×
“As the pregnancy progresses into the second trimester, careful consideration may be given to the use of cyclophosphamide, sharing with the patient the potential risks and benefits associated with this drug [43].”
BackgroundSelf-citationPredictors of maternal and fetal complications in SLE patients: a prospective study
Borella, E., Lojacono, A., Gatto, M., Andréoli, L., Taglietti, M., Iaccarino, L., Casiglia, E., Punzi, L., Tincani, A., & Doria, A. (2014) · Immunologic Research · doi:10.1007/s12026-014-8572-6 · Cited by 105 · cited 1×
“Neverthe-less, 25% of patients taking teratogenic drugs do not use effective contraceptive methods [9].”
BackgroundSelf-citationLindqvist, P. G., Epstein, E., & Olsson, H. L. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03312.x · Cited by 103 · cited 1×
“Many studies [27–31] support vitamin D supplementation in pregnant women with SLE, emphasizing its anti-inflammatory and immunomodulatory effects.”
BackgroundGovoni, M., Bombardieri, S., Bortoluzzi, A., Caniatti, L. M., Casu, C., Conti, F., Vita, S. D., Doria, A., Farina, I., Ferraccioli, G., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/ker310 · Cited by 102 · cited 1×
“This condition should be considered in the differential diagnosis with neuropsychiatric SLE [92].”
BackgroundSelf-citationDefining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?
Doria, A., Mosca, M., Gambari, P. F., & Bombardieri, S. (2005) · PubMed · Cited by 94
Self-citationSkorpen, C. G., Lydersen, S., Gilboe, I., Skomsvoll, J. F., Salvesen, K. Å., Palm, Ø., Koksvik, H. S., Jakobsen, B., & Wallenius, M. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211641 · Cited by 94 · cited 2×
“[41,42].”
BackgroundRole of cytokines in preterm labor and birth.
Park, J. S., Park, C. W., Lockwood, C. J., & Norwitz, E. R. (2005) · PubMed · Cited by 90
Carroll, T. Y., Mulla, M. J., Han, C. S., Brosens, J. J., Chamley, L., Giles, I., Pericleous, C., Rahman, A., Sfakianaki, A. K., Paidas, M. J., et al. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01007.x · Cited by 89 · cited 1×
“A number of in vitro and in vivo studies [56,57] have demonstrated the pathogenicity of these antibodies, which seem to target β 2GPI, expressed by trophoblast cells, leading to tissue damage.”
BackgroundPasoto, S. G., Mendonca, B. B., & Bonfá, E. (2002) · Lupus · doi:10.1191/0961203302lu163oa · Cited by 89 · cited 1×
“Nonetheless, some research [3] has found oophoritis and altered regulation of the hypothalamic–pituitary axis in SLE patients, while hyperprolactinemia is associated with disease flares.”
BackgroundDesai, R. J., Bateman, B. T., Huybrechts, K. F., Patorno, E., Hernández–Díaz, S., Park, Y., Dejene, S. Z., Cohen, J. M., Mogun, H., & Kim, S. C. (2017) · BMJ · doi:10.1136/bmj.j895 · Cited by 80 · cited 1×
“Regarding OGCs, a study by Desai R. et al. [19] showed that high doses of OGCs (prednisone, PDN, >10 mg/day) are an independent risk factor for severe infections (defined as bacterial or opportunistic infections requiring hospitalization) in pregnant women with systemic inflammatory diseases,…”
MethodWei, S., Lai, K., Yang, Z., & Zeng, K. (2017) · Lupus · doi:10.1177/0961203316686704 · Cited by 79 · cited 1×
“Risk is also related to the administration of oral PDN [84,85] and dysfunctions in the maternal or fetal hypothalamic–pituitary axis, which result in elevated placental corticotropin-releasing hormone levels, leading to increased synthesis of cortisol and prostaglandins [86].”
BackgroundVoltolini, C., Torricelli, M., Conti, N., Vellucci, F. L., Severi, F. M., & Petraglia, F. (2013) · Reproductive Sciences · doi:10.1177/1933719113477496 · Cited by 78 · cited 1×
“Risk is also related to the administration of oral PDN [84,85] and dysfunctions in the maternal or fetal hypothalamic–pituitary axis, which result in elevated placental corticotropin-releasing hormone levels, leading to increased synthesis of cortisol and prostaglandins [86].”
BackgroundSystemic Lupus Erythematosus Management in Pregnancy
Dao, K. H., & Bermas, B. L. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 73
Andréoli, L., Gerardi, M. C., Fernandes, M. A., Bortoluzzi, A., Bellando-Randone, S., Brucato, A. L., Caporali, R. F., Chighizola, C. B., Chimenti, M. S., Conigliaro, P., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.08.008 · Cited by 71 · cited 2×
“Assessing disease activity during pregnancy can be challenging for rheumatologists, as there are clinical and laboratory changes in the gestational period that can mimic manifestations of SLE [32].”
BackgroundSelf-citationKeeling, S., Alabdurubalnabi, Z., Aviña-Zubieta, A., Barr, S. G., Bergeron, L., Bernatsky, S., Bourré‐Tessier, J., Clarke, A. E., Baril-Dionne, A., Dutz, J. P., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.171459 · Cited by 68 · cited 1×
“The effectiveness of not-harmful treatments in maintaining disease control should be assessed for at least 3–6 months before conception [2,7,25].”
BackgroundBarsalou, J., Costedoat-Chalumeau, N., Berhanu, A., Nieves, C. E. F., Shah, U., Brown, P., Laskin, C. A., Morel, N., Lévesque, K., Buyon, J. P., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213718 · Cited by 65 · cited 1×
“In contrast, several studies [79–81] have demonstrated that the use of HCQ from the early GWs reduces the risk of NL, even in cases of NL in previous pregnancies.”
ResultBarsalou, J., JAEGGI, E. T., Laskin, C. A., Brown, P., Tian, S. Y., Hamilton, R. M., & Silverman, E. D. (2017) · Rheumatology · doi:10.1093/rheumatology/kex191 · Cited by 61
Maternal deaths in women with lupus nephritis: a review of published evidence
Ritchie, J. P., Smyth, A., Tower, C. L., HELBERT, M., Venning, M., & Garovic, V. D. (2012) · Lupus · doi:10.1177/0961203311434939 · Cited by 59 · cited 1×
“A review by Ritchie J. et al. [61] reported 17 cases of maternal death.”
BackgroundClancy, R. M., Halushka, M. K., Rasmussen, S. E., Lhakhang, T. W., Chang, M., & Buyon, J. P. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800357 · Cited by 59 · cited 1×
“These macrophages were found in the cardiac tissue of fetuses with CHB [71].”
BackgroundLisney, A., Szelinski, F., Reiter, K., Burmester, G. R., Rose, T., & Dörner, T. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210927 · Cited by 58 · cited 1×
“A study conducted by Lisney et al. demonstrated a correlation where mothers of children with congenital heart block (CHB) exhibited significantly higher expression levels of SIGLEC-1 and IFN-α compared to mothers with healthy children [72].”
ResultFetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study
Andersson, N. W., Skov, L., & Andersen, J. T. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa592 · Cited by 58
Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus
Izmirly, P., Saxena, A., & Buyon, J. P. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000414 · Cited by 56 · cited 1×
“Some studies have indicated an increase in biomarkers of inflammation and cardiac distress (C reactive protein, metalloproteinases, NT-ProBNP) in the umbilical cord blood of neonates with cardiac manifestations compared to those without such manifestations [70].”
BackgroundAntioxidant action of antimalarials.
Miyachi, Y., Yoshioka, A., Imamura, S., & Niwa, Y. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.3.244 · Cited by 55 · cited 1×
“Multiple studies [52–54] have indicated that HCQ reduces the synthesis of reactive oxygen species (ROS) and, consequently, their associated damage.”
BackgroundSalomonsson, S., Dzikaite, V., Zeffer, E., Eliasson, H., Ambrosi, A., Bergman, G., Fernlund, E., Theander, E., Öhman, A., Rydberg, A., et al. (2011) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2011.02610.x · Cited by 51 · cited 1×
“Cardiac NL rarely occurs in offspring of women exclusively positive for anti-La/SS-B [62].”
BackgroundRare autoantibodies to cellular antigens in systemic lupus erythematosus
Fredi, M., Cavazzana, I., Quinzanini, M., Taraborelli, M., Cartella, S., Tincani, A., & Franceschini, F. (2014) · Lupus · doi:10.1177/0961203314524850 · Cited by 47 · cited 1×
“Overall, 40% of SLE patients have these antibodies, which are also found in other rheumatological conditions such as Sjogren’s syndrome, undifferentiated connective tissue diseases [66], and rheumatoid arthritis, as well as in the general population [67].”
BackgroundRenal biopsy in the management of lupus nephritis during pregnancy
Chen, T. K., Gelber, A. C., Witter, F. R., Petri, M., & Fine, D. M. (2014) · Lupus · doi:10.1177/0961203314551812 · Cited by 46 · cited 1×
“They reference two studies, one from 2013 involving 197 pregnancy-related biopsies [47] and another from 2015 covering 11 pregnancies [48].”
BackgroundPregnancy outcomes in patients treated with belimumab: Report from real-world experience
Kao, J., Lan, T., Lu, C., Cheng, C., Huang, Y., Shen, C., & Hsieh, S. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.06.005 · Cited by 43
Petri, M., Landy, H. J., Clowse, M. E. B., Gemzoe, K., Khamashta, M. A., Kurtinecz, M., Levy, R. A., Liu, A., Marino, R., Meizlik, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222505 · Cited by 41
An Overview of Neonatal Lupus with Anti-Ro Characteristics
Gryka-Marton, M., Szukiewicz, D., Teliga-Czajkowska, J., & Olesińska, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179281 · Cited by 40 · cited 2×
“Cutaneous manifestations of NL have also been identified in offspring of mothers who have only anti-U1RNP antibodies [69].”
BackgroundYee, C., Akil, M., Khamashta, M. A., Bessant, R., Kilding, R., Giles, I., Farewell, V. T., & Gordon, C. (2012) · Rheumatology · doi:10.1093/rheumatology/kes158 · Cited by 36
Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
Juliao, P., Wurst, K., Pimenta, J. M., Gemzoe, K., Landy, H. J., Moody, M. A., Tilson, H. H., Covington, D. L., Moore, T., Marino, R., et al. (2022) · Birth Defects Research · doi:10.1002/bdr2.2091 · Cited by 36 · cited 1×
“An interim analysis of the Belimumab Pregnancy Registry (BPR) was published in 2022, which showed no increased risk of birth defects in children of women exposed to BEL during pregnancy [20].”
Treatment of preeclampsia with hydroxychloroquine: a review
Rahman, R. A., DeKoninck, P. L. J., Murthi, P., & Wallace, E. M. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1289511 · Cited by 32
Michael, A., Radwan, A. A., Ali, A. K., Abd-Elkariem, A. Y., & Shazly, S. A. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology X · doi:10.1016/j.eurox.2019.100072 · Cited by 32 · cited 2×
“However, multiple studies [75,76] show that first-degree block does not worsen in fetuses with untreated mothers.”
BackgroundPregnancy in Women With Systemic Lupus and Lupus Nephritis
Maynard, S. I., Guerrier, G., & Duffy, M. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.013 · Cited by 32 · cited 1×
“Maynard et al. [46] advocate for the performance of renal biopsies in cases where the differential diagnosis poses a challenge.”
BackgroundPrognosis of Neonates in Pregnant Women with Systemic Lupus Erythematosus
Kim, S., & Lee, J.-H. (2008) · Yonsei Medical Journal · doi:10.3349/ymj.2008.49.4.515 · Cited by 31 · cited 1×
“The risk increased in cases of active disease or renal flares [40,88,89].”
BackgroundContraception and preconception counseling in women with autoimmune disease
Sammaritano, L. R. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.09.003 · Cited by 31 · cited 1×
“However, several studies [5–7] have shown the safety profile of contraception with E-P pills and copper intrauterine devices (IUDs) in patients with inactive diseases, while the use of medicated IUDs should only be considered in specific cases where the benefits outweigh the thrombotic risk [8].”
ResultObstetric management of the most common autoimmune diseases: A narrative review
Fernández‐Buhigas, I. (2022) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2022.1031190 · Cited by 24 · cited 1×
“The percentage of flares varies, ranging from 7 to 20% in women with inactive disease in the six months before pregnancy to 20 to 60% in those with active disease [39].”
BackgroundHuybrechts, K. F., Bateman, B. T., & Hernández–Díaz, S. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.12.1219 · Cited by 19 · cited 2×
“A number of studies and guidelines [12–18] advocate for the continuation or initiation of hydroxychloroquine (HCQ) during pregnancy.”
BackgroundGhalandari, N., Crijns, H. J. M. J., Dolhain, R. J. E. M., Hazes, J. M., & van Puijenbroek, E. (2022) · Lupus · doi:10.1177/09612033221143286 · Cited by 18 · cited 1×
“These results are in line with other limited case series in the literature [21–24].”
ResultHoxha, A., Mattia, E., Zanetti, A., Carrara, G., Morel, N., Costedoat-Chalumeau, N., Brucato, A. L., & Ruffatti, A. (2020) · PubMed · Cited by 17
Powell, M., Hill, D. D., Eudy, A. M., Landy, H. J., & Petri, M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-eular.4484 · Cited by 15 · cited 1×
“These results are in line with other limited case series in the literature [21–24].”
ResultEvers, P. D., Alsaied, T., Anderson, J. B., Cnota, J. F., & Divanovic, A. A. (2018) · Congenital Heart Disease · doi:10.1111/chd.12713 · Cited by 15 · cited 2×
“Evers et al. [74] suggested that utilizing antibody levels to categorize this population can enhance surveillance for CHB. Standard (weekly) screening is not cost-effective and leads to excessive resource utilization.”
BackgroundPathophysiology of the antiphospholipid syndrome (APS)
Meroni, P. L., & Chighizola, C. B. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.09.010 · Cited by 11 · cited 1×
“A number of in vitro and in vivo studies [56,57] have demonstrated the pathogenicity of these antibodies, which seem to target β 2GPI, expressed by trophoblast cells, leading to tissue damage.”
BackgroundPlaidoyer pour le maintien de l'hydroxychloroquine dans les grossesses lupiques
Costedoat-Chalumeau, N., Amoura, Z., Huong, D. U. L. T., Wechsler, B., & Pietté, J. C. (2005) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2005.02.012 · Cited by 11
Petri, M. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003942 · Cited by 7 · cited 1×
“The use of LDA is recommended by the EULAR group [7] and the American College of Obstetrics and Gynecology (ACOG) [51].”
MethodLomarat, W., Pakchotanon, R., Chaiamnuay, S., Narongroeknawin, P., & Asavatanabodee, P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.3355 · Cited by 5 · cited 1×
“Many studies [27–31] support vitamin D supplementation in pregnant women with SLE, emphasizing its anti-inflammatory and immunomodulatory effects.”
BackgroundBreslin, L. C., Ball, E., Armstrong, D., Bell, A. L., Magee, P. J., Laird, E. J., Wallace, J. M. W., & McSorley, E. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-eular.2731 · Cited by 2
Vitamin D in Lupus Patients of Childbearing Age: Are We Doing Enough?
Statache, G., & Brown, S. (2022) · Frontiers in Reproductive Health · doi:10.3389/frph.2022.936810 · Cited by 2
Cited by
Wilson, R. D., Monks, D. T., Sharawi, N., Bamber, J., Panelli, D. M., Sauro, K. M., Shah, P. S., Muraca, G. M., Metcalfe, A., Wood, S. L., et al. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.01.014 · Cited by 22
Single-cell profiling of the peripheral blood immune landscape during mid- and late-stage pregnancy
Gao, F., Li, X., Wang, H., Xu, Z. C., Qian, W., & Bai, G. (2024) · Physiological Genomics · doi:10.1152/physiolgenomics.00041.2024 · Cited by 5
Du, M., Zhang, R., Na, Y., Peng, L., & Bao, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1756063 · Cited by 2
Yerlanova, D., Mukhamediyarov, M., Zimba, O., Korkosz, M., & Koçyiğit, B. F. (2026) · Rheumatology International · doi:10.1007/s00296-026-06086-4 · Cited by 2
Immunologie de la grossesse et du post-partum
Lazaro, E., & Truchetet, M. (2025) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.09.001 · Cited by 1
Metadata
- Authors
- Gamba, A., Zen, M., Depascale, R., Calligaro, A., Gatto, M., Iaccarino, L., & Doria, A.
- Affiliations
- University of Padua (IT)
- University of Turin (IT)
- Corresponding author
- Doria, Andrea
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-06-13
- Volume
- 13
- Issue
- 12
- Pages
- 3454
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11204490
- OpenAlex
- W4399633294
- Cited by
- 25
- References
- 94
- Citations by year
- 2026: 14 · 2025: 9 · 2024: 2
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- systemic lupus erythematosus, pregnancy, preconception counseling, risk stratification, disease activity monitoring, preeclampsia, lupus nephritis, antiphospholipid syndrome, neonatal lupus erythematosus, anti-SSA antibodies, anti-SSB antibodies, fetal growth restriction, small for gestational age, preterm birth, cesarean section, hydroxychloroquine, postpartum monitoring, maternal mortality, fetal outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
